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Background: Hydroxyurea prevents disease complications among patients with sickle cell disease (SCD). Although its efficacy
has been endorsed by the National Health Lung and Blood Institute evidence-based guidelines, its adoption is low, both by patients
with SCD and providers. Mobile health (mHealth) apps provide benefits in improving medication adherence and self-efficacy
among patients with chronic diseases and have facilitated prescription among medical providers. However, mHealth has not been
systematically tested as a tool to increase hydroxyurea adherence nor has the combination of mHealth been assessed at both
patient and provider levels to increase hydroxyurea utilization.
Objective: This study aims to increase hydroxyurea utilization through a combined two-level mHealth intervention for both
patients with SCD and their providers with the goals of increasing adherence to hydroxyurea among patients and improve
hydroxyurea prescribing behavior among providers.
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Methods: We will test the efficacy of 2 mHealth interventions to increase both patient and provider utilization and knowledge
of hydroxyurea in 8 clinical sites of the NHLBI-funded Sickle Cell Disease Implementation Consortium (SCDIC). The patient
mHealth intervention, InCharge Health, includes multiple components that address memory, motivation, and knowledge barriers
to hydroxyurea use. The provider mHealth intervention, Hydroxyurea Toolbox (HU Toolbox), addresses the clinical knowledge
barriers in prescribing and monitoring hydroxyurea. The primary hypothesis is that among adolescents and adults with SCD,
adherence to hydroxyurea, as measured by the proportion of days covered (the ratio of the number of days the patient is covered
by the medication to the number of days in the treatment period), will increase by at least 20% after 24 weeks of receiving the
InCharge Health app, compared with their adherence at baseline. As secondary objectives, we will (1) examine the change in
health-related quality of life, acute disease complications, perceived health literacy, and perceived self-efficacy in taking hydroxyurea
among patients who use InCharge Health and (2) examine potential increases in the awareness of hydroxyurea benefits and risks,
appropriate prescribing, and perceived self-efficacy to correctly administer hydroxyurea therapy among SCD providers between
baseline and 9 months of using the HU Toolbox app. We will measure the reach, adoption, implementation, and maintenance of
both the InCharge Health and the HU Toolbox apps using the reach, effectiveness, adoption, implementation, and maintenance
framework and qualitatively evaluate the implementation of both mHealth interventions.
Results: The study is currently enrolling study participants. Recruitment is anticipated to be completed by mid-2021.
Conclusions: If this two-level intervention, that is, the combined use of InCharge Health and HU Toolbox apps, demonstrates
efficacy in increasing adherence to hydroxyurea and prescribing behavior in patients with SCD and their providers, respectively,
both apps will be offered to other institutions outside the SCDIC through a future large-scale implementation-effectiveness study.
Trial Registration: ClinicalTrials.gov NCT04080167; https://clinicaltrials.gov/ct2/show/NCT04080167
International Registered Report Identifier (IRRID): DERR1-10.2196/16319
(JMIR Res Protoc 2020;9(7):e16319) doi: 10.2196/16319
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Introduction
Sickle Cell Disease and Hydroxyurea Therapy
Sickle cell disease (SCD) is a genetic disorder affecting
approximately 100,000 Americans [1]. The effects of SCD are
devastating, including severe acute and chronic pain, cognitive
disability, renal failure, and lung disease. In controlled clinical
trials, hydroxyurea reduces SCD complications (acute pain and
acute chest syndrome events) and costs [2-5]. In uncontrolled
population studies, hydroxyurea reduces hospitalizations and
mortality, supporting the effectiveness of hydroxyurea outside
of research studies [6-11]. Hydroxyurea is prescribed in a
once-daily dosing, and blood counts are monitored every 1 to
3 months and titrated to reach a maximum tolerated dose defined
by mild, reversible myelosuppression [12]. Given the evidence
of its benefit, in 2014, the National Institutes of Health/National
Heart, Lung, and Blood Institute (NHLBI) released guidelines
recommending the use of hydroxyurea [13].
Hydroxyurea Underutilization and Efforts to Improve
Its Use
Despite overwhelming evidence of its positive effects,
hydroxyurea is vastly underutilized [14,15]. In analyses
conducted using Medicaid claims data, fewer than 50% of adults
were ever prescribed or initiated hydroxyurea, and only about
30% of those who initiated treatment achieved adequate
adherence levels [16-19]. Among children, adherence was
higher; however, the number of children who were prescribed
hydroxyurea was low [20-22]. Barriers to prescribing
hydroxyurea include providers’ reluctance due to lack of
knowledge about the drug and appropriate dosing, low patient
acceptance due to insufficient knowledge or misconceptions
about risks and benefits, and forgetfulness leading to poor
adherence [14,15,20,23-28]. Patient forgetfulness related to
daily hydroxyurea use is a common barrier [29] and may be
exacerbated by the prevalence of cognitive dysfunction in
patients with SCD, including working memory deficits and low
motor processing speed [30-32]. Additionally, negative
perceptions toward hydroxyurea are strongly associated with
lower adherence to this medication [33]. Among prescribers,
the anticipation of poor patient adherence dissuades medical
providers from prescribing hydroxyurea [19,20,34].
Improved adherence to hydroxyurea achieves higher fetal
hemoglobin (HbF) levels (thereby decreasing polymerization
of the sickle hemoglobin), fewer hospital admissions, a higher
health-related quality of life, and reductions in health care costs,
resulting in major improvements in overall clinical outcomes
[35,36].
In an effort to address the underutilization of evidence-based
recommendations, including that of hydroxyurea, the NHLBI
established the Center for Translation Research and
Implementation Science in 2014 [37], and in 2016, the NHLBI
funded the SCD Implementation Consortium (SCDIC) [38].
The goal of the SCDIC is to support multilevel and
multicomponent interventions to address the quality gap in the
delivery of evidence-based treatments for patients with SCD
between the ages of 15 and 45 years (when the gap in care
delivery is the greatest) employing implementation science
strategies. The Integration of mHealth into SCD Care to Increase
Hydroxyurea Utilization study is one of the planned multicenter
studies within the SCDIC that utilizes the implementation
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science framework and evaluation strategies to increase the
adaptation and dissemination of evidence-based treatments
among individuals with SCD.
Mobile Health Technology and Its Potential for Sickle
Cell Disease Care and Hydroxyurea Utilization
The existing body of research provides support for mHealth
interventions to improve treatment adherence across a variety
of chronic conditions, including SCD [39-42]. Among patients
with SCD, approximately 85% to 97% of patients own
smartphones [29,43], and some use this technology to monitor
pain [44,45].
Preliminary studies suggest that mHealth interventions can
specifically be used to improve hydroxyurea adherence. In
children with SCD, the use of text message reminders combined
with direct-observed therapy (via video recording) and financial
incentives for 6 months significantly increased hydroxyurea
adherence and hematologic markers [46,47]. In a study of 81
adolescents with SCD who received text messaging to improve
hydroxyurea adherence, significant increases in relevant
hematological indices (HbF, mean corpuscular volume [MCV],
hemoglobin [Hb]) and significant reduction of hemolysis
markers (absolute reticulocyte count [ARC], bilirubin, and
lactate dehydrogenase [LDH]) were observed [43]. Collectively,
these findings suggest that hydroxyurea use can be improved
with the use of mHealth via improved adherence. A systematic
review of mHealth apps for SCD has confirmed these findings
but observed that the sample size of most studies was not large,
and the studies were mostly observational or retrospective [42].
mHealth is also increasingly used to aid physicians in their
medical decision making [48] and to facilitate consultations
with other providers and experts in their areas of expertise
[49,50], highlighting the broad applicability of mHealth, not
only for patients but also for medical providers. In a survey of
health care providers, more than 70% of physicians had
smartphones, and 77% of nurses and doctors used medical apps
[51]. The ease of access and increasing familiarity with apps
has led to a growing focus on developing disease-specific
medical apps for health care providers.
Logic Model of Change to Increase Hydroxyurea
Utilization
We conceptualized a logic model that guided the development
of mHealth apps to foster hydroxyurea utilization among patients
and improve provider prescribing behaviors. This logic model
used intervention mapping methods to develop and adapt
behavioral models for testing mHealth as an intervention to
increase hydroxyurea use. Intervention mapping is a systematic
framework for developing, implementing, and adapting theory-
and evidence-based interventions [52]. Using the knowledge of
barriers to the uptake and adherence to hydroxyurea therapy,
we mapped the determinants of hydroxyurea utilization (Figure
1). These determinants are hypothesized to drive the behaviors
involved in patients’ and providers’ use of hydroxyurea and
correspond to the barriers of hydroxyurea use that were
identified through literature review and the results of a needs
assessment within the study participating sites. Importantly, the
patient and provider interventions were developed and aimed
at the determinants that could affect the behavior involved in
taking and prescribing hydroxyurea; the ultimate goal (the
behavioral outcome) is to foster greater patient adherence to
hydroxyurea (Figure 1).
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Figure 1. Logic model of change to increase hydroxyurea utilization. This logic model maps all barriers identified by literature review and needs
assessment analysis, with a focus on the determinants of the behaviors to hydroxyurea use. The intervention addresses the determinants of hydroxyurea
use at both the patient and provider levels. If this two-level intervention is successful, hydroxyurea utilization will increase, as reflected by increased
hydroxyurea adherence, resulting in improved health-related quality of life and reduction in acute health care utilization.
Hydroxyurea Adherence Behaviors for Patients
To guide the development of the mHealth app for patients, we
used the health belief model (HBM) as the framework [53] for
behavioral change. The HBM explains health behaviors and
focuses on the attitudes and beliefs of individuals. The
health-related action driving the increased use of hydroxyurea
includes 5 constructs: perceived susceptibility, perceived
severity, perceived benefits, perceived barriers, and self-efficacy.
Notably, these 5 constructs represent modifiable factors that,
together, can influence the increased use of hydroxyurea. The
patient intervention focuses on these 5 constructs as the specific
mechanisms to address the change in behavior (ie, medication
adherence).
Behavioral Model for Mobile Health Utilization Among
Medical Providers
The acceptance of new technology by users, including new
mHealth innovations, determines its successful adaptation and,
therefore, its intended effects. The perceptions of health care
professionals regarding their ability to use mobile health care
systems to accomplish a health care task is an important
determinant that should also be considered when new technology
is implemented. The technology acceptance model [54,55] is a
conceptual model that explains the intent to use new information
technology (eg, mHealth) or information science among users,
including medical providers. Perceived usefulness, perceived
ease of use, compatibility, and mobile health care systems
self-efficacy are the most important determinants of the behavior
intent of providers [56]. We considered all of these drivers and
assessed them in the context of the hydroxyurea prescriber to
develop the provider HU Toolbox as follows:
• Perceived usefulness: SCD providers require concise
information to support clinical decision making while
prescribing hydroxyurea.
• Compatibility: The previous experience SCD providers
have in using mobile technology was considered.
• Perceived ease of use: The perception of SCD providers
that mobile technology can be integrated with their
electronic health system and their daily clinical routine.
• Mobile health care systems self-efficacy: SCD providers’
perception that mHealth could help with the task of
prescribing hydroxyurea.
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Description of the Mobile Health Interventions
InCharge Health Mobile App
InCharge Health was developed using a user-centered design
approach, in which the patients’ input in its development was
obtained through an iterative process that started with a
design-thinking session, followed by surveys and interviews
that investigated barriers and facilitators of hydroxyurea use
and preferences for its use [57]. A prototype was developed and
further refined using information derived from focus groups
with patients with SCD.
The InCharge Health mobile app includes several features to
increase patient engagement, including the following: (1) daily
customizable text message reminders that can be sent if the
patient is hospitalized, (2) a daily recording of hydroxyurea
adherence and pain score, (3) a 7-day streak that tracks daily
adherence and graphing of adherence against pain symptoms,
(4) a communication feature that allows the patient to connect
to the health care provider and other patients, and (5) an
education bank that provides information about SCD and
hydroxyurea risks and benefits in layman’s terms (Figure 2).
Additionally, InCharge Health has an accountability partner
feature that specifies a person (eg, friend, family member) who
will receive notifications if the user has not documented the use
of hydroxyurea for >4 hours (from the time of receipt of the
daily reminder) and is encouraged to remind the patient to take
their medication. The InCharge Health app does not collect any
protected health information and functions in places with Wi-Fi
accessibility or using the phone’s data plan.
Figure 2. Features of the InCharge Health app for patients. (A) Push notifications will come daily and will prompt the patient participant to mark if
the dose was taken, not taken, or be reminded later. (B) Customization of the push notification messages, time of the day, and choice of the accountability
partner. (C) A daily pain and mood tracker is available and captures pain level and mood changes. (D) Graphing of pain level versus pain is available
for the past 7 days. (E) A link to the patient portal accesses the patient’s electronic medical chart, clinic numbers, and patient-led discussion forums.
(F) A large resource bank is available with links to vetted educational websites, educational material, and educational videos and is included.
Hydroxyurea Toolbox Mobile App
The HU Toolbox is a decision-support tool developed with input
from pediatricians, internists, and hematologists from several
academic centers in North Carolina and members of the
Community Care of North Carolina medical home system. The
HU Toolbox app contains NHLBI guidelines adapted for
pediatric and adult providers (guidelines and recommendations
stratified by age). In addition to being an information source,
the app contains artificial intelligence algorithms guiding the
clinician on how to prescribe hydroxyurea and monitor its effects
through a chatbot feature, which simulates a human conversation
using text messaging. The HU Toolbox chatbot feature guides
clinicians on how to recognize hydroxyurea side effects and
how to manage them (Figure 3). Finally, a built-in SCD
specialist feature is available, allowing providers to reach and
consult SCD experts in their region, who respond to enquiries
within 24 hours.
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Figure 3. Features of the HU Toolbox mobile app: The HU Toolbox provides tools for medical providers prescribing hydroxyurea. The app provides
a chatbot for users to ask questions about how to dose and monitor hydroxyurea effects and side effects (left panel). In addition, there is educational
material available in a library (right panel) as well as the ability to chat directly with a local SCD specialist. HU Toolbox: Hydroxyurea Toolbox; SCD:
sickle cell disease.
Specific Aims and Objectives
Aim 1: Improve Patient Adherence to Hydroxyurea
We will compare adherence to hydroxyurea at baseline with
adherence after 6 months of InCharge Health among adolescents
and adults with SCD. Our primary hypothesis is that, among
patients with SCD, hydroxyurea therapy adherence will increase
by 20% at 24 weeks after receiving the InCharge Health
intervention, compared with their hydroxyurea adherence
measured at baseline. Adherence will be measured by the
proportion of days covered (PDC; the ratio of the number of
days the patient is covered by the medication to the number of
days in the treatment period) [58]. The rationale for choosing
the primary end point is because a 20% increase in PDC is a
clinically meaningful change and represents an increment of
approximately 1.4 additional days of hydroxyurea use in a
week’s period. Our conservative estimated increase of 20%
refill is based on previous studies that used text messages to
increase hydroxyurea adherence and observed adherence
increases as high as 60% [59]. The timing of the primary end
point (at 24 weeks) is such that it will allow sufficient time to
observe clinical and laboratory changes from increased
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hydroxyurea adherence, as it may take an average of 4 to 6
months to observe full hydroxyurea effects.
Aim 1a: To Assess Patient Engagement and Behaviors
Related to Use of InCharge Health
We will evaluate the consistent use of the app, patient
satisfaction, and continued use of the app beyond the study
period.
Aim 1b: To Examine the Improvement in Clinical and
Patient Outcomes Related to the Use of InCharge Health
We will investigate changes in the proportion of patients with
PDC >80%, hematologic indices, acute health care utilization,
health-related quality of life, and perceived self-efficacy for
medication use between baseline and 24 weeks after receiving
the InCharge Health intervention.
Aim 2: Improve Provider Hydroxyurea Prescribing
Behaviors
Among providers using the HU Toolbox app, we will examine
the changes in knowledge of hydroxyurea benefits and risks as
well as perceived self-efficacy to correctly prescribe
hydroxyurea therapy between baseline and after 9 months of
using the HU Toolbox intervention.
Aim 2a: To Examine Clinical Characteristics and
Provider Engagement and Behaviors Related to the Use
of the HU Toolbox
We will evaluate the frequency with which providers use the
app and provider satisfaction and continued use of the app
beyond the study period.
Aim 2b: To Assess Combined Effects of the Patient and
Provider Mobile Health Interventions on Hydroxyurea
Adherence and Acute Health Care Utilization.
We will examine if the changes in hydroxyurea adherence,
emergency department visits, and hospitalizations are enhanced
by the use of InCharge Health and HU Toolbox concomitantly.
Aim 3
We will qualitatively evaluate the barriers and facilitators of
the implementation of mHealth interventions. We will examine
the strategies used to support the implementation of mHealth
interventions and evaluate the facilitators and barriers to
implementation from multiple stakeholder perspectives: patients,
providers, and administrators.
Methods
The study protocol is reported in accordance with the Standard
Protocol Items for Clinical Trials (SPIRIT), where applicable
(SPIRIT checklist; Multimedia Appendix 1) [60].
Evaluation Framework
Key considerations to begin implementing mHealth for
hydroxyurea utilization include recruitment in diverse care
settings and estimating the reach, effectiveness, adoption,
implementation, and maintenance of the apps, which are the 5
components of the RE-AIM framework [61]. RE-AIM is a useful
framework to evaluate the utility of mHealth to foster
hydroxyurea utilization and to broaden the future applicability
and dissemination of the apps [62,63]. RE-AIM will be used in
this study to measure the overall impact and robustness of apps
to achieve improved patient adherence to hydroxyurea and better
prescribing practices of this drug.
Study Design
The study design is a nonrandomized, closed cohort trial where
the 2 mHealth apps will be introduced sequentially in 8
participating clinic sites over 3 time periods (Figure 4). A cohort
of subjects recruited from within each site will be followed over
each time period in which the unit of analysis will be the patient.
Within each site, there will be one or more treatment clinics.
Each provider within a participating clinic will receive the HU
Toolbox intervention for 9 months, while each patient participant
will receive the InCharge Health app intervention for 6 months.
The providers (physicians and advance care practitioners) will
begin receiving the provider app 2 months before patients (at
the same site) initiate the use of the patient app. There will be
a staggered 6 months between groups of sites (Figure 4). The
study rollout will allow for a baseline evaluation, followed by
preparation and introduction of the provider app (education of
providers and remaining staff), followed by implementation of
the apps, and evaluation postimplementation (Figure 4).
Implementing the interventions at the first 2 sites will allow us
to determine any challenges and adapt to ensure increased uptake
and implementation for the following sites.
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Figure 4. Study time periods: 2 or 3 groups of sites will enter the study at each of the 3 time periods, and 4 study phases will take place during each
study period. T0: introduction of HU Toolbox to providers, provider enrollment, and baseline data collection. T1: introduction of InCharge Health to
patients, patient enrollment, and baseline data collection. T2: All enrolled patients and provider participants were followed as active study participants.
Each patient will use the InCharge Health app for 6 months, and each provider will use the HU Toolbox app for 9 months. Postintervention data collection:
this phase reflects the sustainability of the interventions. We will continue to provide technical support for both patient and provider applications and
measure continued utilization of the applications and adherence to hydroxyurea. Solid triangle denotes InCharge Health and HU Toolbox interventions.
HU Toolbox: Hydroxyurea Toolbox.
Study Setting
The study will be carried out at 8 diverse SCDIC participating
clinical sites and their subsites. The study settings are variable
and include academic and nonacademic sites within urban,
suburban, and rural settings. The context for the program is
diverse and presents an opportunity to test mHealth in different
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settings, with not only geographical but also structural
differences using the RE-AIM evaluation framework.
Participants
Potential participants will be approached during a nonemergent
clinic visit. The study coordinator will verify that the participant
(patient or provider) meets the study eligibility criteria
(Textboxes 1 and 2), and will approach them in person, phone,
or via electronic media about enrolling in the study. Participants
will sign an informed consent before study participation (unless
a waiver of consent is granted by the local institutional review
board). If the participant is a minor, the legal guardian will sign
the consent and assent will be obtained. Participants will be
considered enrolled when consent is obtained, and inclusion
criteria have been confirmed. All providers within each practice
will be approached and invited to participate. All clinics will
have each provider register within the app to allow
provider-specific data. Each site will maintain a local enrollment
log and will also confirm enrollment status in the data
management system.
Textbox 1. Inclusion and exclusion criteria for patient participants.
Inclusion criteria
• Between 15 and 45 years
• Treated at or affiliated with one of the sickle cell diseases implementation consortium sites
• English speaking
• Confirmed sickle cell disease diagnosis by a hemoglobin fractionation test
• Owns a cellular/mobile smartphone (either Android or iOS)
• Hydroxyurea therapy:
• Already receiving hydroxyurea therapy (at least one previous prescription for hydroxyurea in the past 3 months) or
• Initiating hydroxyurea therapy (the first prescription must be written on the same day as study enrollment). Patient participants who initiate
hydroxyurea on the same day of study enrollment will not contribute to the total target accrual for the site, but rather will be analyzed as a
separate group
Exclusion criteria
• Known current pregnancy
• A red blood cell transfusion in the past 60 days. This is necessary as transfusions will mask laboratory markers and clinical changes from
hydroxyurea
• Currently using consistency. another cellphone app or a web-based tool (electronic health tool) to increase hydroxyurea adherence
Textbox 2. Inclusion criteria and the exclusion criterion for provider participants.
Inclusion criteria
• Physician (including physician in training) or advanced practice provider (nurse practitioner or physician assistant) who cares for at least one
patient with sickle cell disease for an anticipated minimum of 12 months from study enrollment
• Access to a cellular/mobile smartphone (either Android or iOS) or access to a computer with internet connectivity (HU Toolbox app can be
accessed via the internet on any device)
• Exclusion criterion
• Currently using another phone app or a web-based tool to increase hydroxyurea adherence for patients with SCD in his/her practice
Implementation Strategies
To promote the uptake of both the patient and provider mHealth
apps into practice, we will employ multiple implementation
strategies. Sites will be provided with a list of discrete strategies
(eg, education strategies such as conducting ongoing training
and regular check-ins with patients and providers regarding app
functionality). Each clinical site will be able to select a strategy
or strategies that best fit their context. All sites will be required
to provide training on the apps for both patients and providers
using a standard training protocol, which is detailed in the study
standard operating procedure document. Research staff will
guide the participants on the installation of InCharge Health
and HU toolbox on the participants’mobile devices (or computer
in the case of providers). Using a developed script, the research
team will provide instructions about app settings, explain how
to use the app, and answer any questions. Before participants
leave the clinic, patients will be asked to demonstrate their
knowledge and ability to use the app. Centralized technical
assistance (by the app developers) will be provided for both
apps to ensure a high level of fidelity in their implementation.
Specifically, patients and providers will be given a number to
call and an email address if they have questions regarding the
app or the study in general. Data related to technical problems
related to the apps will be tracked to evaluate their functionality.
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Efficacy will be determined by assessing the impact of InCharge
Health on hydroxyurea by measuring the change in PDC from
baseline (before intervention) to week 24 (primary outcome).
For the PDC, the pharmacy that fills the most prescription claims
within the target therapeutic category for a specific patient
within the calendar range will be assigned responsibility for the
patient. The pharmacy name and number where hydroxyurea
is filled will be collected by the research coordinators at each
study visit, and refill information will be requested from these
pharmacies. All prescription drug refills, from all dispensing
pharmacies, will be ascertained.
Secondary Outcomes
These include daily recorded adherence on the app; proportion
of patients with PDC ≥80%; laboratory markers of hydroxyurea
response (HbF, Hb concentration, MCV, ARC, absolute
neutrophil count, indirect bilirubin, LDH); health care utilization
(hospitalizations and emergency department visits);
health-related quality of life; perceived health literacy, patient
medication self-efficacy, and implementation outcomes.
Data Collection
After enrolling, patient participants will return at 12 and 24
weeks for study visits, where study-related procedures will be
conducted (Table 1). Provider participants will complete an
assessment of self-confidence in prescribing hydroxyurea at
baseline and at the study exit (Table 2). Three months after
study completion, InCharge Health and HU Toolbox usage will
be assessed via analysis of app statistics. Additionally, at study
completion, we will solicit feedback from patients and providers
regarding the clinical usefulness of the apps and their usability
and impact. (Tables 1 and 2). Clinical and implementation
measures will be assessed using the RE-AIM framework, both
for InCharge Health (Table 3) and HU Toolbox (Table 4).
We will conduct 15 semistructured key-informant interviews
(30-60 min) with multiple key stakeholders toward the end of
app implementation at each of the study sites. We will
purposively sample and interview patients and providers
(physicians and advance care practitioners) from each site
according to mHealth app use (low uptake vs high uptake). The
RE-AIM framework was used to develop the interview guides
and systematically assess barriers and facilitators. For example,
patients will be asked how using InCharge Health impacts the
way they take hydroxyurea, whereas providers will be asked
how using the HU Toolbox impacts the way they prescribe
hydroxyurea. Patients and providers will also be asked about
why they chose to participate in the study, training received for
the apps, and whether they would continue to use the apps after
the study is complete. We also plan interviews with clinic
administrators to gain a clinic-level perspective on factors that
influenced implementation.
JMIR Res Protoc 2020 | vol. 9 | iss. 7 | e16319 | p. 10https://www.researchprotocols.org/2020/7/e16319
(page number not for citation purposes)
Hankins et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX













———xb—aAge, sex, race, ethnicity, marital status, educational attainment, health in-
surance type, income, occupation
———x—Informed consent
Patient adherence to hydroxyurea (Aim 1) and the combined effects of the patient and provider mHealth c interventions (Aim 2b)
Hydroxyurea adherence
xxxxxProportion of daily coverage
—xx—App daily adherence statistics and 7-day recall measure using the brief
medication questionnaire




———x—MTDd dose (mg/kg/day) and date reached
xxxx—Current dose (mg/kg/day and mg/day)
xxxxxBiomarkers of hydroxyurea effect (HbFe%, Hbf, MCVg, ANCh, ARCi,
indirect bilirubin, LDHj)
Health care utilization
xxxxxDate and discharge diagnosis of EDk visits, acute care/infusion visit hospi-
talizations
Self-efficacy and health literacy
—x—x—PROMISl self-efficacy for medication short form
—x—x—Perceived health literacy
Health-related quality of life and pain report
—x—x—ASCQ-Mem pain impact, ASCQ-Me pain episode frequency and severity,
PROMIS pain quality
Engagement of patients related to the use of InCharge Health app (Aim 1a)
Implementation measures
—x———See Tables 3 and 4
mHealth satisfaction
—xx——Perceived usability and acceptability of mHealth intervention (MARSn)
[64]
Evaluation of facilitators and barriers to implementation of the mHealth app (Aim 3)
Barriers and facilitators to implementation
xx———Qualitative interviewso
aDenotes not done at this timepoint.
bx denotes done at this timepoint.
cmHealth: mobile health.
dMTD: maximum tolerated dose.
eHbF: fetal hemoglobin.
fHb: hemoglobin.
gMCV: mean corpuscular volume.
hANC: absolute neutrophil count.
iARC: absolute reticulocyte count.
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lPROMIS: Patient-Reported Outcomes Measurement Information System.
mASCQ-Me: adult sickle cell quality of life measurement information system.
nMARS: mobile app rating scale.
oConducted at the end of the study at each site.







——bxaAge, sex, race, ethnicity, type of professional (physician, nurse practitioner, physician assistant),
years in practice
———Informed consent
Improve provider hydroxyurea awareness, prescribing, and monitoring behaviors (Aim 2)
Self-efficacy and hydroxyurea knowledge
—xxPerceived confidence in prescribing hydroxyurea to patients with SCDc, including correct daily
dosing
Engagement of providers related to the use of the HU Toolbox app (Aim 2a)
Implementation and mHealth satisfaction
—x—Perceived usability and acceptability of mHealth intervention (MARSd scale) [64]
Hydroxyurea prescribing practices (clinic-level measures)
xxxTotal number of patients with SCD
xxxNumber of patients eligible to receive hydroxyurea therapy at provider participant’s sitee
xxxNumber of hydroxyurea-eligible patients who are prescribed hydroxyurea (all sickle genotypes)e
Evaluation of facilitators and barriers to implementation of the mHealth app (Aim 3)
Barriers and facilitators to implementation
—x—Qualitative interviewsf
ax denotes done at this time point.
bDenotes not done at this time point.
cSCD: sickle cell disease.
dMARS: mobile app rating scale.
eHydroxyurea eligibility will follow the 2014 National Health Lung and Blood Institute guidelines as follows: hydroxyurea should be offered to all
children with homozygous sickle hemoglobin mutation (HbSS) and compount heterozygous sickle hemoglobin and null beta thalassemia
(HbSβ0-thalassemia) age ≥9 months and prescribed to all symptomatic adults with HbSS/HbSβ0-thalassemia, that is, >3 episodes of severe vaso-occlusion
in the preceding 9 months [13].
fConducted at the end of the study at each site.
For additional information on Implementation and mHealth
satisfaction, please refer to Tables 3 and 4
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Table 3. The reach, effectiveness, adoption, implementation, and maintenance evaluation measures of InCharge Health implementation.
Data sourcesDomains and measures
Reach •• Clinic data collection
forms
Sociodemographic characteristics of patients at each site
• Proportion and representativeness of patients screened for the study (numerator)
among all patients who receive hydroxyurea treatment (denominator) at each site • Clinic population demo-
graphics and treatment
data, study database
• Proportion and representativeness of patients eligible for the study (numerator) among
all patients who receive hydroxyurea treatment (denominator) at each site
• Screening log• Proportion and representativeness of patients participating/enrolled in the study (nu-
merator) among all patients who receive hydroxyurea treatment and were eligible
(denominator) at each site
• Qualitative interviews
Effectiveness •• Prescription drug
claims (PDC for hy-
droxyurea refills)
Primary outcome
• >20% improvement in the PDCa for hydroxyurea among those receiving the interven-
tion





• Change in Quality of life, self-efficacy, perceived health literacy
• Change in percentage of patients with EDb visits, hospitalizations since the last study
visit • Medical chart abstrac-
tion• Change in biomarkers of hydroxyurea effect (MCVc, ANCd, ARCe, indirect bilirubin,
HbFf, Hbg, LDHh) • Qualitative interviews
Adoption •• Clinic administrative
data and data collection
forms
Proportion and description of clinics in each site agreeing to support InCharge Health
• Proportion and description of providers in each clinic agreeing to support InCharge
Health (ie, proportion enrolled on the study)
• Qualitative interviews
Implementation •• App usage statisticsConsistency with which sites are able to implement the app as planned
• •Qualitative assessment of any adaptations or enhancement to recruitment strategies
needed to meet enrollment by the clinic, by site
Patient surveys
• Qualitative interviews
• Assess adaptation of training needed to improve InCharge Health implementation at
each site
• Engagement with the app: percentage, number, and representativeness of patients
who used InCharge Health during the study period (low, medium-low, medium, or
high use; in the entire practice)
• Proportion, number, and characteristics of patients who complete the study among
those who initiate the use of the app but then later discontinue at each site
• Percentage and characteristics of patients who reported satisfaction with the InCharge
Health app (MARSk scale)
• Clinic/provider assessment of perceptions of InCharge Health app for further scale-
up or sustainability—ease of use, preferred features, and so on
Maintenance/sustainability •• Pharmacy claims data
(PDC for hydroxyurea
refills)
Extent to which program leaders express a desire or intent to continue providing the
app with patients at the conclusion of the research
• Percentage of patients who continue to use the app beyond the study period and their
representativeness • App use statistics
• Clinic data collection
forms
• Qualitative interviews
aPDC: proportion of days covered.
bED: emergency department.
cMCV: mean corpuscular volume.
dANC: absolute neutrophil count.




iASCQ-Me: adult sickle cell quality of life measurement information system.
jPROMIS: Patient-Reported Outcomes Measurement Information System.
kMARS: mobile app rating scale.
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Table 4. The reach, effectiveness, adoption, implementation, and maintenance evaluation measures of Hydroxyurea Toolbox implementation.
Data sourcesMeasuresDomains
Adoption—clinic •• Institutional data to describe clinics (eg, size, case
mix, years in service, regional sociodemographics
of SCDb patients)
Proportion and representativeness of clinics that agree to
support the HUaToolbox
• Clinic data collection form
• Qualitative interviews
Adoption—provider •• Provider surveyCharacteristics of providers at each site (eg, specialty,
years in practice, sociodemographics, level of expertise) • Clinic data collection form
• Proportion and representativeness of eligible providers
approached in the study (numerator) among all providers
(denominator)
• Proportion and representativeness of enrolled providers in
the study (numerator) among all eligible providers (denom-
inator) at each site
Effectiveness •• Provider surveyNumber and proportion of providers demonstrating im-
proved knowledge and self-efficacy in hydroxyurea admin-
istration
• Medical chart abstraction
• Qualitative interviews
• Percentage of patients who were prescribed hydroxyurea
per provider
Implementation •• App usage statisticsConsistency with which sites are able to implement the
use of the Toolbox app as planned • Provider survey
• Engagement with the app: Percentage, number, and repre-
sentativeness of providers that appropriately used HU
Toolbox app (low or high use; in the entire practice)
• Qualitative interviews
• Percentage of providers who reported satisfaction with HU
Toolbox app (MARSc scale)
• Percentage of patients whose provider used the Toolbox
at each site
• App usage statistics
Maintenance/sustainability •• App usage statisticsExtent to which program leaders express a desire or intent
to offer or encourage the use of the Toolbox app by their
clinical providers at the conclusion of the research
• Clinic data collection form
• Qualitative interviews
• Percentage of providers who continue to use the provider
app beyond the study period, and representativeness
• Percentage of providers who continue to prescribe hydrox-
yurea to their patients
aHU: Hydroxyurea.
bMARS: mobile app rating scale.
bSCD: sickle cell disease.
Sample Size
Sample sizes were calculated for the primary outcome, PDC,
using simulations based on the linear mixed model in the
analysis plan. First, we modeled the baseline values. Results
from Candrilli et al [18] indicated a left-skewed distribution for
adherence measured by medication possession ratio. We expect
a similarly left-skewed distribution for PDC. The baseline PDC
was therefore modeled as PDC=100 × X, where X follows a
beta distribution with parameters 1.0 and 0.6667. This produced
a left-skewed distribution with a mean of 60% (SD 30%), closely
paralleling a mean of 0.60 (SD 0.32) reported by Candrilli et al
[18] for the medication possession ratio. We included site-to-site
variation in baseline PDC by adding a site-specific random
variate, drawn from a normal distribution with a mean of 0 (SD
0.2) to the 2 parameters. The resulting site-specific means are
between 56% and 69%, with a probability of .95. Baseline values
were modeled by drawing random samples from these beta
distributions.
To model treatment response, including site-to-site variation in
response, we added the expected response of 12% plus a
site-specific random variable drawn from a normal distribution
with a mean of 0 (SD 5.48) to each baseline value for PDC.
Residual intrasubject variation at each time point ( in the linear
mixed model) was included by adding a separate random
variable drawn from a normal distribution with a mean of 0 to
each simulated PDC value. Assuming that approximately 25%
of 24-week PDC values will be missing, each 24-week
observation was randomly deleted with a probability of .25.
The treatment effect is measured against noise, which includes
residual intrasubject variation and site-to-site variation in
treatment response. Therefore, power was investigated by
specifying SDs for the 2 variance components, generating
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simulated data sets of 8 sites with 46 subjects recruited per site,
and fitting the linear mixed model to each data set. Power was
estimated as the percentage of simulated data sets producing a
statistically significant increase in PDC among 1000 simulated
data sets.
Baseline and posttreatment PDC are expected to be moderately
to strongly correlated (ie, subjects with lower baseline PDC will
tend to have lower posttreatment PDC than those with higher
starting values). This expectation places limits on the variance
components because the correlation varies inversely with the
variance of the measurements. Variance components that result
in a correlation of 0.50 also result in approximately 90% power
to detect a treatment effect under the conditions specified in the
simulations. A correlation of 0.50 is well below expectations,
indicating that the study will have considerable power to detect
the posited treatment effect under the specified conditions.
Patients who initiate hydroxyurea on the same day of enrollment
will not contribute to the primary aim but will be analyzed as
a separate subset of participants for the secondary outcomes
only, as no baseline PDC will be able to be calculated for them.
The total number of physicians and advanced practitioners in
all participating sites is approximately 100. All of them will be
approached, and the total number of those who agree to
participate will be computed.
Methods of Analysis
Aim 1: Improve Patient Adherence to Hydroxyurea
Changes in PDC in response to treatment will be evaluated
using a linear mixed model. Predictors will include a random
effect for the study site, a fixed binary indicator for treatment,
the interaction of the site with treatment, and a random effect
for the subject nested within the site. The interaction is included
to test for differences in PDC changes among sites. The random
subject effect is included to account for the correlation induced
by repeated observations of the same subjects. If the interaction
is not statistically significant, then it will be dropped from the
model, and inferences about treatment response will be based
on the main effect of treatment. If the treatment does indicate
site-to-site variation in change in PDC, then pairwise
comparisons between changes at the sites will be made using
the Tukey honestly significant difference to control the type I
error rate.
Aim 1a: To Assess Patient Engagement and Behaviors
Related to the Use of InCharge Health
Counts and scores of the measures in Textboxes 1 and 2 will
be graphed with box plots by month. Using the box plots from
the last month, patients will be classified into 4 levels of app
usability: low (<25% of the daily app usage), medium-low
(25%-49% of the daily app usage), medium-high (50%-74% of
the daily app usage) or high (75%-100% of the daily app usage)
by initially using quartiles of the implementation measures, then
examining the box plots of the measures and adjusting as needed
to create 4 clinically meaningful groupings of app users. App
uptake will be computed at the end of the study at each site.
Aim 1b: To Examine the Improvement in Clinical and
Patient Outcomes Related to the Use of InCharge Health
The linear mixed model will also be employed to evaluate
changes in laboratory biomarkers of hydroxyurea effect, quality
of life, health literacy, self-efficacy, and satisfaction with the
app (as listed in Textboxes 1 and 2) between baseline and 24
weeks. The models will include the treatment indicator and site
as usual, a 4-level categorical predictor of use of the app (low,
medium-low, medium-high, and high) and the interaction of
app use with the treatment. A statistically significant interaction
will be interpreted to mean that changes in an outcome in
response to the treatment varied with use of the app. The Tukey
HSD test will then be employed to identify the pairwise
differences that contributed to the significant effect. If no
variation with use of the app is found, then the interaction will
be dropped from the model as described earlier. The models for
laboratory biomarkers will also include time since starting
hydroxyurea and sickle cell genotype as covariates. Models,
including site-level characteristics of urban versus rural and
academic versus community will also be created to determine
if heterogeneity in the site characteristics impacts intervention
efficacy. For dichotomous outcomes, such as PDC ≥80% versus
<80% and hospitalization and emergency room visits during
the study, generalized linear mixed models (GLMM) will be
employed with a logit link to relate the outcome to the predictors
[65]. The GLMM models will follow the same format as the
linear mixed model above with fixed effects for intervention/app
use and random effects for sites and subjects within sites.
Aim 2: Improve Provider Hydroxyurea Prescribing
Behaviors
Given the limited number of providers expected to enroll in the
study, many of the analyses are simplified and do not account
for the across the site and across time complexities of the study
design. As such, the results should be considered exploratory.
Using baseline data, providers will be classified into 4
categories, according to the level of comfort and expertise in
caring for patients with SCD (Multimedia Appendix 2). We
will attempt to evaluate the implementation and effectiveness
outcomes stratified by this provider categorization to better
understand how expertise impacts the implementation and
effectiveness of the HU Toolbox app.
Aim 2a: To Examine Clinic Characteristics and Provider
Engagement and Behaviors Related to the Use of the
HU Toolbox
Uptake of the HU Toolbox by providers after 9 months will be
assessed using the implementation measures identified in Table
4 (under implementation). Box plots for each measure for all
participants will be combined and stratified by expertise level.
One-way analysis of variance or Kruskal-Wallis tests will
examine differences in the uptake of the HU Toolbox across
expertise levels (Figure 5). If the null hypothesis is rejected,
Dunn’s test will be employed for multiple comparisons. If an
experience level has fewer than 5 providers, it will be combined
with the closest lower experience level. The results of these
analyses will be used to identify clinically meaningful low and
high toolbox app uptake groups for Aim 2b.
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Figure 5. Study group comparisons according to each aim. The introduction and investigation of each intervention is performed sequentially. A total
of 4 possible intervention combinations will be evaluated and compared: provider and patient use the intervention (patient and provider blue boxes),
neither provider nor patient uses the intervention (patient and provider blue boxes), provider uses the intervention, but the patient does not (provider:
blue box and patient: red box), and the patient uses the intervention, but the provider does not (provider red box and patient blue box). HU Toolbox:
Hydroxyurea Toolbox; SCD: sickle cell disease.
Aim 2b: To Assess the Combined Effects of the Patient
and Provider Mobile Health Interventions on
Hydroxyurea Adherence and Health Care Utilization
Figure 5 shows the sequential introduction and investigation of
each intervention. A total of 4 possible intervention
combinations will be evaluated and compared: provider and
patient use the intervention, neither provider nor patient uses
the intervention, the provider uses the intervention, but the
patient does not, and the patient uses the intervention, but the
provider does not. Comparisons within and across groups will
be conducted. This analysis seeks to identify the impact of both
the patient and provider interventions on hydroxyurea adherence
and acute health care utilization (count of emergency department
visits and hospitalizations per patient) at baseline and at 6
months. These outcomes will be treated as Poisson variables in
GLMMs with log link functions. Predictors will include an
indicator for time (baseline vs 6 months), a categorical predictor
for the 4 levels of InCharge Health app uptake defined in Aim
1a, an indicator for low (less than one day per month use of the
app in a 6-month period) versus high provider (one or more
days per month use of the app in a 6-month period) toolkit app
uptake, the interaction between patient and provider uptake,
and a random effect to account for clustering of baseline and
9-month measures within providers. The Tukey HSD test will
be employed for pairwise comparisons among predictor
categories if statistically significant effects of patient
characteristics, provider characteristics, or interactions are found.
App uptake will be computed at the end of the study at each
site.
Aim 3: Qualitatively Evaluate the Barriers and
Facilitators of the Implementation of Mobile Health
Interventions
Sufficient understanding of the contextual factors in the
implementation of mHealth interventions is critical to ensuring
future scale-up and translation of study findings [66]. As such,
for Aim 3, we will build on the RE-AIM quantitative findings
by using qualitative inquiry to identify common barriers and
facilitators across the sites and to support the development of
implementation strategies for use in future studies. Data will
be collected and analyzed concurrently using a mixed methods
approach, where qualitative data will be secondary to the
quantitative assessment [67].
Results
The study is currently enrolling participants (NCT 04080167).
Recruitment is anticipated to be completed by mid-2021. The
results are expected to be submitted for publication toward the
end of the project in early 2022.
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Hydroxyurea has proven its efficacy in treating patients with
SCD, but its utilization in real-world settings is suboptimal.
mHealth interventions have increasingly been used to foster
greater adherence to medication and to facilitate the use of
therapies by prescribers. In this study, we propose to overcome
the barriers to hydroxyurea utilization by using a 2-level
mHealth intervention: the InCharge Health app for patients and
the HU Toolbox app for providers. We will examine the uptake
of these 2 interventions using implementation science strategies.
Although acknowledging the multilevel barriers to hydroxyurea
utilization, our approach will address the main barriers affecting
hydroxyurea adoption and use among patients with SCD and
focus on improving prescribing practices among providers. This
2-level approach will allow us to demonstrate the clinical effect
of mHealth interventions to improve adherence among patients
(the main outcome of the study) and, at the same time, address
and evaluate other barriers to optimal care among providers.
Our findings will enhance the subsequent implementation of
mHealth in diverse settings and populations, as the participating
sites are substantially different in geographical settings (eg,
urban, suburban, and rural) and population characteristics. The
study will provide preliminary data on the integration of
mHealth into clinical care, its clinical influence, and evaluate
how well this strategy is accepted, adopted, and sustained in
diverse clinical settings.
The Integration of mHealth into SCD Care to Increase
Hydroxyurea Utilization study will be the first large-scale
prospective trial to investigate mHealth interventions for SCD
using an implementation science framework to improve
hydroxyurea effectiveness and adaptation while incorporating
implementation strategies to maximize the integration of the
apps into clinical practice. If successful, this model may create
a new paradigm in which mHealth interventions can be
integrated into routine clinical practice in real-world settings.
This approach focuses on the complexity of therapies for chronic
diseases in which the lack of widespread adaptation is
multifactorial and should account for multiple stakeholders.
This study has some limitations. PDC is one of the multiple
measures of medication adherence; however, it allows us to
pragmatically estimate adherence as it approximates optimal
adherence when PDC is ≥80%. PDC is an accepted quality
measure of adherence and the metric used by the Centers for
Medicare and Medicaid Services as the process measure of
adherence [68]. PDC best reflects the real-world setting as
opposed to the use of electronic bottles or video-recorded daily
dose ingestion (ie, directly observed adherence measure). The
Integration of mHealth into SCD Care to Increase Hydroxyurea
Utilization study does not include randomization of mHealth
interventions, and this approach may be considered as the next
step in our research.
Few prospective intervention studies to improve hydroxyurea
adherence in SCD using mHealth have been undertaken [42].
In general, they have shown positive results in improving daily
hydroxyurea utilization and other outcomes, such as
health-related quality of life [69,70]. The Integration of mHealth
into SCD Care to Increase Hydroxyurea Utilization study
expands the existing studies because it (1) addresses all the
important behavior determinants of suboptimal hydroxyurea
utilization at both the patient and provider levels, (2)
incorporates them into mHealth apps for both patients and
providers, and (3) studies a large population of patients with
SCD and their providers in different geographic and clinical
settings. Finally, engagement with mHealth interventions will
be of particular importance during the study, as sustained use
of mHealth intervention may decrease over time. Our study
plans to evaluate engagement with mHealth interventions by
monitoring app usability (frequency of use and specific features
used) in addition to performing qualitative analysis to better
ascertain factors influencing engagement with mHealth.
In summary, the Integration of mHealth into SCD Care to
Increase Hydroxyurea Utilization study is the first study
investigating the efficacy and implementation of mHealth
interventions on 2 levels to improve hydroxyurea utilization,
namely the patient and the provider, in a large multicenter
prospective study. Importantly, the development of both
mHealth interventions was informed by the stakeholders
involved (patients with SCD and their providers). If successful,
this study will help define the role of mHealth in increasing
hydroxyurea utilization at multiple levels and will allow for a
large-scale implementation trial that will rigorously test which
strategies are most effective in disseminating mHealth to more
patients with SCD and their providers.
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